PTEN loss in the continuum of common cancers, rare syndromes and mouse models (original) (raw)

• Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998).
  Article CAS PubMed Google Scholar
• Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 95, 15587–15591 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Marsh, D. J. et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7, 507–515 (1998).
  Article CAS PubMed Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS PubMed Google Scholar
• Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356–362 (1997).
  Article CAS PubMed Google Scholar
• Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16, 64–67 (1997).
  Article CAS PubMed Google Scholar
• Hobert, J. A. & Eng., C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. 11, 687–694 (2009).
  Article CAS PubMed Google Scholar
• Manning, B. & Cantley, L. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hlobilkova, A. et al. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp. Cell Res. 256, 571–577 (2000).
  Article CAS PubMed Google Scholar
• Weng, L. P., Brown, J. L. & Eng., C. PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet. 10, 599–604 (2001).
  Article CAS PubMed Google Scholar
• Dey, N. et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 68, 1862–1871 (2008).
  Article CAS PubMed Google Scholar
• Davidson, L. et al. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 29, 687–697 (2010).
  Article CAS PubMed Google Scholar
• Poon, J. S., Eves, R. & Mak, A. S. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 9, 4450–4454 (2010).
  Article CAS PubMed Google Scholar
• Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170 (2007).
  Article CAS PubMed Google Scholar
• Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144, 187–199 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Qiao, X., Zhang, L., Gamper, A. M., Fujita, T. & Wan, Y. APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity. Cell Cycle 9, 3904–3912 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127–150 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Orloff, M. S. & Eng., C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 27, 5387–5397 (2008).
  Article CAS PubMed Google Scholar
• Marsh, D. J. et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum. Mol. Genet. 8, 1461–1472 (1999).
  Article CAS PubMed Google Scholar
• Pezzolesi, M. G. et al. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes. Am. J. Hum. Genet. 79, 923–934 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, X. P. et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am. J. Hum. Genet. 73, 404–411 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Alimonti, A. et al. Subtle variations in Pten dose determine cancer susceptibility. Nature Genet. 42, 454–458 (2010).
  Article CAS PubMed Google Scholar
• Shen-Li, H., Koujak, S., Szablocs, M. & Parsons, R. Reduction of Pten dose leads to neoplastic development in multiple organs of _Pten_shRNA mice. Cancer Biol. Ther. 10, 1194–1200 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Alvarez-Nunez, F. et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16, 17–23 (2006).
  Article CAS PubMed Google Scholar
• Garcia, J. M. et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosom. Cancer 41, 117–124 (2004).
  Article CAS PubMed Google Scholar
• Ho, C. M. et al. PTEN promoter methylation and LOH of 10q22–23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol. Oncol. 112, 307–313 (2009).
  Article CAS PubMed Google Scholar
• Kang, Y. H., Lee, H. S. & Kim, W. H. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. 82, 285–291 (2002).
  Article CAS PubMed Google Scholar
• Koul, D. PTEN signaling pathways in glioblastoma. Cancer Biol. Ther. 7, 1321–1325 (2008).
  Article CAS PubMed Google Scholar
• Salvesen, H. B. et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22–26 (2001).
  Article CAS PubMed Google Scholar
• Soria, J. et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8, 1178–1184 (2002).
  CAS PubMed Google Scholar
• Huse, J. T. et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23, 1327–1337 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, J. G. et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta 411, 846–852 (2010).
  Article CAS PubMed Google Scholar
• Poliseno, L. et al. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 3, ra29 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Tamguney, T. & Stokoe, D. New insights into PTEN. J. Cell Sci. 120, 4071–4079 (2007).
  Article CAS PubMed Google Scholar
• Wang, X. & Jiang, X. Post-translational regulation of PTEN. Oncogene 27, 5454–5463 (2008).
  Article CAS PubMed Google Scholar
• Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141–156 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nature Genet. 19, 348–355 (1998).
  Article CAS PubMed Google Scholar
• Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563–1568 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Stambolic, V. et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60, 3605–3611 (2000).
  CAS PubMed Google Scholar
• Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169–1178 (1998).
  Article CAS PubMed Google Scholar
• Hollander, M. C. et al. Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia 10, 866–872 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Keniry, M. & Parsons, R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27, 5477–5485 (2008).
  Article CAS PubMed Google Scholar
• Daikoku, T. et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 68, 5619–5627 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Li, G. et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129, 4159–4170 (2002).
  CAS PubMed Google Scholar
• Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
  Article CAS PubMed Google Scholar
• Suzuki, A. et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523–534 (2001).
  Article CAS PubMed Google Scholar
• Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774–1783 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Tsuruta, H. et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res. 66, 8389–8396 (2006).
  Article CAS PubMed Google Scholar
• Yanagi, S. et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J. Clin. Invest. 117, 2929–2940 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Stiles, B. L. et al. Selective deletion of Pten in pancreatic β cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol. Cell. Biol. 26, 2772–2781 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Marsh, V. et al. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nature Genet. 40, 1436–1444 (2008).
  Article CAS PubMed Google Scholar
• Gustafson, S., Zbuk, K. M., Scacheri, C. & Eng., C. Cowden syndrome. Semin. Oncol. 34, 428–434 (2007).
  Article CAS PubMed Google Scholar
• Saal, L. H. et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genet. 40, 102–107 (2008).
  Article CAS PubMed Google Scholar
• Perez-Tenorio, G. et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13, 3577–3584 (2007).
  Article CAS PubMed Google Scholar
• Sangale, Z. et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl. Immunohistochem. Mol. Morphol. 19, 173–183 (2011).
  Article CAS PubMed Google Scholar
• Singh, B., Ittmann, M. M. & Krolewski, J. J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosom. Cancer 21, 166–171 (1998).
  Article CAS PubMed Google Scholar
• Li, Y. et al. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol. Biol. 2, 2 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Schade, B. et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J. Biol. Chem. 284, 19018–19026 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Blumenthal, G. M. & Dennis, P. A. PTEN hamartoma tumor syndromes. Eur. J. Hum. Genet. 16, 1289–1300 (2008).
  Article CAS PubMed Google Scholar
• Risinger, J. I., Hayes, A. K., Berchuck, A. & Barrett, J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57, 4736–4738 (1997).
  CAS PubMed Google Scholar
• Maxwell, G. L. et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58, 2500–2503 (1998).
  CAS PubMed Google Scholar
• Tashiro, H. et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57, 3935–3940 (1997).
  CAS PubMed Google Scholar
• Zhou, X. P., Kuismanen, S., Nystrom-Lahti, M., Peltomaki, P. & Eng., C. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum. Mol. Genet. 11, 445–450 (2002).
  Article CAS PubMed Google Scholar
• Beiner, M. E. et al. Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol. Biomarkers Prev. 15, 1636–1640 (2006).
  Article CAS PubMed Google Scholar
• Kanamori, Y. et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 7, 892–895 (2001).
  CAS PubMed Google Scholar
• Vilgelm, A. et al. Akt-mediated phosphorylation and activation of estrogen receptor α is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 66, 3375–3380 (2006).
  Article CAS PubMed Google Scholar
• Milam, M. R. et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am. J. Obstet. Gynecol. 196, 247 (2007).
  Article PubMed CAS Google Scholar
• Wang, H. et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am. J. Pathol. 160, 1481–1486 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Lloyd, K. M. & Dennis, M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann. Intern. Med. 58, 136–142 (1963).
  Article PubMed Google Scholar
• Dahia, P. L. et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 57, 4710–4713 (1997).
  CAS PubMed Google Scholar
• Halachmi, N. et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosom. Cancer 23, 239–243 (1998).
  Article CAS PubMed Google Scholar
• Frisk, T. et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosom. Cancer 35, 74–80 (2002).
  Article CAS PubMed Google Scholar
• Puxeddu, E. et al. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutat. Res. 570, 17–32 (2005).
  Article CAS PubMed Google Scholar
• Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C. & Pandolfi, P. P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genet. 27, 222–224 (2001).
  Article CAS PubMed Google Scholar
• Yeager, N., Klein-Szanto, A., Kimura, S. & Di Cristofano, A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 67, 959–966 (2007).
  Article CAS PubMed Google Scholar
• Guigon, C. J., Zhao, L., Willingham, M. C. & Cheng, S. Y. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28, 509–517 (2009).
  Article CAS PubMed Google Scholar
• Wang, S. I. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183–4186 (1997).
  CAS PubMed Google Scholar
• Sano, T. et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59, 1820–1824 (1999).
  CAS PubMed Google Scholar
• Schmidt, E. E. et al. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol. 58, 1170–1183 (1999).
  Article CAS PubMed Google Scholar
• Kwon, C. H. et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nature Genet. 29, 404–411 (2001).
  Article CAS PubMed Google Scholar
• Backman, S. A. et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nature Genet. 29, 396–403 (2001).
  Article CAS PubMed Google Scholar
• Groszer, M. et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc. Natl Acad. Sci. USA 103, 111–116 (2006).
  Article CAS PubMed Google Scholar
• Wei, Q. et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res. 66, 7429–7437 (2006).
  Article CAS PubMed Google Scholar
• Xiao, A., Wu, H., Pandolfi, P. P., Louis, D. N. & Van Dyke, T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1, 157–168 (2002).
  Article CAS PubMed Google Scholar
• Zheng, H. et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129–1133 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, H. et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb. Symp. Quant. Biol. 73, 427–437 (2008).
  Article CAS PubMed Google Scholar
• Kwon, C. H. et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 68, 3286–3294 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Lundgren, R., Kristoffersson, U., Heim, S., Mandahl, N. & Mitelman, F. Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. Cancer Genet. Cytogenet. 35, 103–108 (1988).
  Article CAS PubMed Google Scholar
• Cairns, P. et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997–5000 (1997).
  CAS PubMed Google Scholar
• Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nature Rev. Cancer 1, 34–45 (2001).
  Article CAS Google Scholar
• Abate-Shen, C. et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 63, 3886–3890 (2003).
  CAS PubMed Google Scholar
• Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393–406 (2005).
  Article CAS PubMed Google Scholar
• King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genet. 41, 524–526 (2009).
  Article CAS PubMed Google Scholar
• Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genet. 41, 619–624 (2009).
  Article CAS PubMed Google Scholar
• Kwabi-Addo, B. et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl Acad. Sci. USA 98, 11563–11568 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, e59 (2003).
• Guldberg, P. et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660–3663 (1997).
  CAS PubMed Google Scholar
• Mirmohammadsadegh, A. et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66, 6546–6552 (2006).
  Article CAS PubMed Google Scholar
• Lahtz, C., Stranzenbach, R., Fiedler, E., Helmbold, P. & Dammann, R. H. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J. Invest. Dermatol. 130, 620–622 (2010).
  Article CAS PubMed Google Scholar
• Mikhail, M. et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin. Cancer Res. 11, 5153–5157 (2005).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc. Natl Acad. Sci. USA 106, 6279–6284 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Inoue-Narita, T. et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res. 68, 5760–5768 (2008).
  Article CAS PubMed Google Scholar
• You, M. J. et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl Acad. Sci. USA 99, 1455–1460 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544–552 (2009).
  Article CAS PubMed Google Scholar
• Scheper, M. A., Nikitakis, N. G., Sarlani, E., Sauk, J. J. & Meiller, T. F. Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 101, 625–631 (2006).
  Article PubMed Google Scholar
• Yokomizo, A. et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475–479 (1998).
  Article CAS PubMed Google Scholar
• Kohno, T., Takahashi, M., Manda, R. & Yokota, J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosom. Cancer 22, 152–156 (1998).
  Article CAS PubMed Google Scholar
• Marsit, C. J. et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 36, 768–776 (2005).
  Article CAS PubMed Google Scholar
• Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene Suppl. 28, S24–S31 (2009).
  Article CAS Google Scholar
• Sos, M. L. et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256–3261 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Buckingham, L. et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer 126, 1630–1639 (2010).
  CAS PubMed Google Scholar
• Iwanaga, K. et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 68, 1119–1127 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Perren, A. et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157, 1097–1103 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Stanger, B. Z. et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8, 185–195 (2005).
  Article CAS PubMed Google Scholar
• Xu, X., Ehdaie, B., Ohara, N., Yoshino, T. & Deng, C. X. Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 29, 674–686 (2010).
  Article CAS PubMed Google Scholar
• Yao, Y. J. et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18, 3181–3185 (1999).
  Article CAS PubMed Google Scholar
• Yeh, K. T. et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. Cancer Invest. 18, 123–129 (2000).
  Article CAS PubMed Google Scholar
• Dong-Dong, L., Xi-Ran, Z. & Xiang-Rong, C. Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J. Cell. Mol. Med. 7, 67–71 (2003).
  Article PubMed PubMed Central Google Scholar
• Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl Acad. Sci. USA 101, 2082–2087 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Cairns, P. et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16, 3215–3218 (1998).
  Article CAS PubMed Google Scholar
• Wang, D. S. et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int. J. Cancer 88, 620–625 (2000).
  Article CAS PubMed Google Scholar
• Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675–680 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• van Nederveen, F. H. et al. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J. Pathol. 209, 274–280 (2006).
  Article CAS PubMed Google Scholar
• Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647–50 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Silva, A. et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 118, 3762–3774 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gronbaek, K., Zeuthen, J., Guldberg, P., Ralfkiaer, E. & Hou-Jensen, K. Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91, 4388–4390 (1998).
  CAS PubMed Google Scholar
• Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410–3415 (1998).
  CAS PubMed Google Scholar
• Scarisbrick, J. J., Woolford, A. J., Russell-Jones, R. & Whittaker, S. J. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 95, 2937–2942 (2000).
  CAS PubMed Google Scholar
• Chen, M. et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten± mice. Genes Dev. 20, 1569–1574 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Guertin, D. A. et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148–159 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bayascas, J. R., Leslie, N. R., Parsons, R., Fleming, S. & Alessi, D. R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/- mice. Curr. Biol. 15, 1839–1846 (2005).
  Article CAS PubMed Google Scholar
• Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl Acad. Sci. USA 98, 10320–10325 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Blando, J. et al. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am. J. Pathol. 174, 1869–1879 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, X. et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211–221 (2008).
  Article CAS PubMed Google Scholar
• Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Krueger, D. A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801–1811 (2010).
  Article CAS PubMed Google Scholar
• Marsh, D. J. et al. Rapamycin treatment for a child with germline PTEN mutation. Nature Clin. Pract. Oncol. 5, 357–361 (2008).
  Article CAS Google Scholar
• Mahalingam, D., Sankhala, K., Mita, A., Giles, F. J. & Mita, M. M. Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol. 5, 291–303 (2009).
  Article CAS PubMed Google Scholar
• Easton, J. B. & Houghton, P. J. mTOR and cancer therapy. Oncogene 25, 6436–6446 (2006).
  Article CAS PubMed Google Scholar
• Slomovitz, B. M. et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116, 5415–5419 (2010).
  Article CAS PubMed Google Scholar
• Yuan, R., Kay, A., Berg, W. J. & Lebwohl, D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2, 45 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075–1083 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pal, S. K., Reckamp, K., Yu, H. & Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 19, 1355–1366 (2010).
  Article CAS PubMed Google Scholar
• Teresi, R. E. et al. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone. Int. J. Cancer 118, 2390–2398 (2006).
  Article CAS PubMed Google Scholar
• Liu, X. et al. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J. Clin. Invest. 120, 2497–2507 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dedes, K. J. et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010).
  Article PubMed CAS Google Scholar
• McEllin, B. et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457–5464 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004).
  Article CAS PubMed Google Scholar
• Esteva, F. J. et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status. association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177, 1647–1656 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
  Article CAS PubMed Google Scholar
• Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567–571 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Freeman, D. et al. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res. 66, 6492–6496 (2006).
  Article CAS PubMed Google Scholar
• Engel, C. et al. Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol. Biomarkers Prev. 19, 2859–2868 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Trimboli, A. J. et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461, 1084–1091 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hamada, K. et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 19, 2054–2065 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Groszer, M. et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294, 2186–2189 (2001).
  Article CAS PubMed Google Scholar
• Gregorian, C. et al. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J. Neurosci. 29, 1874–1886 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, S. et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl Acad. Sci. USA 103, 1480–1485 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Korsten, H., Ziel- van der Made, A., Ma, X., van der Kwast, T. & Trapman, J. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS ONE 4, e5662 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Mulholland, D. J. et al. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the _Pten_-null prostate cancer model. Cancer Res. 69, 8555–8562 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475–482 (2006).
  Article CAS PubMed Google Scholar
• Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518–522 (2006).
  Article CAS PubMed Google Scholar
• Peng, C. et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115, 626–635 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Furnari, F. B., Huang, H. J. & Cavenee, W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58, 5002–5008 (1998).
  CAS PubMed Google Scholar
• Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323–334 (1999).
  Article CAS PubMed Google Scholar
• Georgescu, M. M. et al. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 60, 7033–7038 (2000).
  CAS PubMed Google Scholar
• Adey, N. B. et al. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 60, 35–37 (2000).
  CAS PubMed Google Scholar
• Georgescu, M. M., Kirsch, K. H., Akagi, T., Shishido, T. & Hanafusa, H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl Acad. Sci. USA 96, 10182–10187 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Vanhaesebroeck, B. & Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561–576 (2000).
  CAS PubMed PubMed Central Google Scholar
• Hynes, N. E. & MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177–184 (2009).
  Article CAS PubMed Google Scholar
• Dowling, R. J., Topisirovic, I., Fonseca, B. D. & Sonenberg, N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804, 433–439 (2010).
  Article CAS PubMed Google Scholar
• Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457–468 (2002).
  Article CAS PubMed Google Scholar
• O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500–1508 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
  Article CAS PubMed Google Scholar
• Edelman, G. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. Am. Soc. Clin. Oncol. Abstr. 28, 3004 (2010).
  Article Google Scholar
• Von Hoff, D. D. et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Am. Soc. Clin. Oncol. Abstr. 28, 2541 (2010).
  Article Google Scholar
• O'Brien, C. et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 16, 3670–3683 (2010).
  Article CAS PubMed Google Scholar
• Floris, G. et al. Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. Am. Soc. Clin. Oncol. Abstr. 28, 10020 (2010).
  Article Google Scholar
• Jimeno, A. et al. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Am. Soc. Clin. Oncol. Abstr. 28, 3089 (2010).
  Article Google Scholar
• Le Cras, T. D. et al. Inhibition of PI3K by PX-866 prevents transforming growth factor-α-induced pulmonary fibrosis. Am. J. Pathol. 176, 679–686 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Baselga, J. et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. Am. Soc. Clin. Oncol. Abstr. 28, 3003 (2010).
  Article Google Scholar
• Buonamici, S. et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2, 51ra70 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Furman, R. R. et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. Am. Soc. Clin. Oncol. Abstr. 28, 3032 (2010).
  Article Google Scholar
• Burris, H. et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Am. Soc. Clin. Oncol. Abstr. 28, 3005 (2010).
  Article Google Scholar
• Chiorean, E. G. et al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. Am. Soc. Clin. Oncol. Abstr. 27, 2558 (2009).
  Google Scholar
• Garlich, J. R. et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68, 206–215 (2008).
  Article CAS PubMed Google Scholar
• Dolly, S. et al. A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma. Am. Soc. Clin. Oncol. Abstr. 28, 3079 (2010).
  Article Google Scholar
• Brana, I. et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. Am. Soc. Clin. Oncol. Abstr. 28, 3030 (2010).
  Article Google Scholar
• Prasad, G. et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 11 Feb 2011 (doi: 10.1093/neuonc/noq193).
• Mallon, R. et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol. Cancer Ther. 9, 976–984 (2010).
  Article CAS PubMed Google Scholar
• Venkatesan, A. M. et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem. 53, 2636–2645 (2010).
  Article CAS PubMed Google Scholar
• Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
  Article CAS PubMed Google Scholar
• Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
  Article CAS PubMed Google Scholar
• Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Dancey, J. mTOR signaling and drug development in cancer. Nature Rev. Clin. Oncol. 7, 209–219 (2010).
  Article CAS Google Scholar
• Squarize, C. H., Castilho, R. M. & Gutkind, J. S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 68, 7066–7072 (2008).
  Article CAS PubMed Google Scholar
• Zhang, W. et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 69, 7466–7472 (2009).
  Article CAS PubMed Google Scholar
• Granville, C. A. et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin. Cancer Res. 13, 2281–2289 (2007).
  Article CAS PubMed Google Scholar
• Stelzer, M. K. et al. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev. Res. 3, 1542–1551 (2010).
  Article CAS Google Scholar
• Cen, O. & Longnecker, R. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr Virus-related Burkitt's lymphoma. Mol. Cancer Ther. 31 Jan 2011 (doi: 10.1158/1535-7163.MCT-10-0833).
• Seager, C. M. et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev. Res. 2, 1008–1014 (2009).
  Article CAS Google Scholar
• Namba, R. et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin. Cancer Res. 12, 2613–2621 (2006).
  Article CAS PubMed Google Scholar
• Diegel, C. R., Cho, K. R., El-Naggar, A. K., Williams, B. O. & Lindvall, C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 70, 9143–9152 (2010).
  Article CAS PubMed Google Scholar
• Chiu, C. W., Nozawa, H. & Hanahan, D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J. Clin. Oncol. 28, 4425–4433 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288–298 (2010).
  Article CAS PubMed Google Scholar
• Richards, D. A. et al. Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC). Am. Soc. Clin. Oncol. Abstr. 28, 3531 (2010).
  Article Google Scholar
• Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053–4062 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Z., Tan, F., Liewehr, D. J., Steinberg, S. M. & Thiele, C. J. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J. Natl Cancer Inst. 102, 758–770 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tolcher, A. W. et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). Am. Soc. Clin. Oncol. Abstr. 27, 3503 (2009).
  Article CAS Google Scholar
• Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956–1967 (2010).
  Article CAS PubMed Google Scholar
• Mao, J. H. et al. Genetic interactions between Pten and p53 in radiation-induced lymphoma development.. Oncogene 22, 8379–8385 (2003).
  Article CAS PubMed Google Scholar
• Birck, A., Ahrenkiel, V., Zeuthen, J., Hou-Jensen, K. & Guldberg, P. . Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Invest. Dermatol. 114, 277–280 (2000).
  Article CAS PubMed Google Scholar
• Celebi, J. T., Shendrik, I., Silvers, D. N. & Peacocke, M. . Identification of PTEN mutations in metastatic melanoma specimens.. J. Med. Genet. 37, 653–657 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Rahman, M. A. et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int. J. Cancer 100, 152–157 (2002).
  Article CAS PubMed Google Scholar
• Chen, S. et al. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis 13, 59–69 (2010).
  Article PubMed PubMed Central Google Scholar
• Shao, J., Washington, M. K., Saxena, R. & Sheng, H. et al. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin. Carcinogenesis 28, 2476–2483 (2007).
  Article CAS PubMed Google Scholar
• Zhou, X. P. et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol. 161, 439–447 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Heald, B. et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 139, 1927–1933 (2010).
  Article CAS PubMed Google Scholar